Overview

Neoadjuvant Adebrelimab + DOS in Locally Advanced Resectable Gastric Cancer

Status:
RECRUITING
Trial end date:
2026-04-26
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of adebrelimab combined DOS in neoadjuvant treatment of locally advanced resectable gastric cancer.
Phase:
PHASE2
Details
Lead Sponsor:
Tang-Du Hospital
Collaborator:
Jiangsu Hengrui Pharmaceutical Co., Ltd.